

- **Full Name:** Ji-Yeon Kim
 - **Current Position & Affiliation:** Assistant professor, Samsung Medical Center, Sungkyunkwan University School of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- 2001-2004 Korea Advanced Institute of Science & Technology (KAIST), Biology, BSc
- 2004-2008 Seoul National University College of Medicine, M.D.
- 2012-2020 Seoul National University College of Medicine, Ph.D.

• Professional Experience:

- 2009-2013 Residency, Seoul National University Hospital, Dept. of Internal Medicine
- 2013-2015 Fellowship, Seoul National University Hospital, Division of Hematology & Oncology
- 2015-2020 Clinical Assistant Professor, Samsung Medical Center, Department of Medicine, Division of Hematology & Oncology, Breast Cancer Center
- 2020- Assistant Professor, Samsung Medical Center, Center, Department of Medicine, Division of Hematology & Oncology, Breast Cancer Center
- 2022- Assistant Professor, Sungkyunkwan University School of Medicine, Internal Medicine

• Professional Organizations:

- 2022- Global Breast Cancer Conference, a member of scientific committee
- 2022- Korean Society of Medical Oncology, a member of scientific committee
- 2022- Korean Cancer Association, a member of review committee

• Main Scientific Publications:

1. **Kim JY**, Oh JM, Lee SK, Yu J, Lee JE, Kim SW, et al. Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. *Front Oncol.* 2022;12:903372.
2. **Kim JY**, Nam SJ, Lee JE, Yu J, Chae BJ, Lee SK, et al. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. *Cancer Res Treat.* 2022;54(4):1091-8.
3. **Kim JY**, Kim J, Cho EY, Park YH, Ahn JS, Kim KM, Im YH. Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer. *Front Oncol.* 2023 Mar 16;13:1146934

4. **Kim JY**, Jung J, Kim KM, Lee J, Im YH. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors. *Cancer Med.* 2023 Jun;12(11):12438-12451
5. **Kim JY**, Shin J, Ahn JS, Park YH, Im YH. Real world experience of second-line treatment strategies after palbociclib and letrozole: Overall survival in metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer. *Cancers (Basel).* 2023;15(13).3431
6. **Kim JY**, Park S, Cho EY, Lee JE, Jung HH, Chae BJ, et al. Genomic Characteristics of Triple Negative Apocrine Carcinoma: A Comparison to Triple Negative Breast Cancer. *Exp Mol Med.* 2023. <https://doi.org/10.1038/s12276-023-01030-z>